Intersociety Collaborative Joint Companion Meeting at
Sunday, March 17, 2019
National Harbor 8
1:30 - 5:00 PM
CME 3 SAM 3
Current and Future Revolution in Pathology Practice:
(Focus on) Immuno-oncology and Cancer Epigenetics
ASIP/ASCP will bring together 4 speakers from across two unique disciplines of pathology to discuss the practice, science, and challenges of immuno-oncology and cancer epigenetics, intended to inform and educate residents, fellows, and practicing pathologists. The course will begin with a practical discussion of Immuno-oncology (IO) in current practice (Mamatha Chivukula, Sutter Health, CA) from the perspective of a community-based pathologist. This segment will review the current landscape of “companion diagnostics” in the immuno-oncology space, including but not limited to treatment-specific biomarker assessment (PD-1), tumor mutational burden, sequencing, etc., with specific emphasis on treatment selection challenges, quality across the testing/reporting spectrum, pitfalls, and practical solutions. This will be followed up by a discussion of cutting-edge science in IO (Mike Milone, UPenn) with emphasis on those technologies and tools that are likely to move into clinical practice soon. This same approach to cancer epigenetics (David Williams, UNC) will be revealed and discussed in the third presentation. Both of these cutting-edge talks will identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics. To finish off, a “future talk” focused on how cancer epigenetics will affect patient care and everyday diagnostics will be presented (Idriss M. Bennani-Baiti, President, Cancer Epigenetics Society, Vienna, Austria).This portion will assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care.
Course Learning Objectives
Upon completion of this educational activity, the learner will be able to:
  • Review the current landscape of “companion diagnostics” in the immuno-oncology space including but not limited to treatment-specific biomarker assessment (PD-1), tumor mutational burden, sequencing, etc. with specific emphasis on treatment selection challenges, quality across the testing/reporting spectrum, pitfalls, and practical solutions
  • Identify current and forthcoming basic and translational science in immuno-oncology and cancer epigenetics likely to generate immediate or future diagnostics
  • Assess the implications for the practicing pathologist of current and future science in cancer epigenetics to daily practice and best patient care
Organizers and Session Chairs
Danny Milner, MD, MSc
ASCP
David Williams, MD, PhD
ASIP
Share Below!